{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T20:15:54Z","timestamp":1784924154672,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["005206Q123"],"award-info":[{"award-number":["005206Q123"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["005583Q123"],"award-info":[{"award-number":["005583Q123"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["009319Y125"],"award-info":[{"award-number":["009319Y125"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["advancesinpediatrics.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Pediatrics"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.yapd.2025.11.001","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T11:31:50Z","timestamp":1779190310000},"page":"179-190","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gastrointestinal and Pancreatic Manifestations of Cystic Fibrosis in the Era of Highly Effective Modulators"],"prefix":"10.1016","volume":"73","author":[{"given":"Sasha-Jane","family":"Abi-Aad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridevi","family":"Narayanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Racha T.","family":"Khalaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.yapd.2025.11.001_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/ph16030410","article-title":"Elexacaftor-tezacaftor-ivacaftor: a life-changing triple combination of CFTR modulator drugs for cystic fibrosis","volume":"16","author":"Bacalhau","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"19","key":"10.1016\/j.yapd.2025.11.001_bib3","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.yapd.2025.11.001_bib4","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3 open-label study of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.yapd.2025.11.001_bib5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.202301-0084OC","article-title":"Phase 3 open-label clinical trial of elexacaftor\/tezacaftor\/ivacaftor in children aged 2-5 years with cystic fibrosis and at least one F508del allele","volume":"208","author":"Goralski","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.yapd.2025.11.001_bib7","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S2213-2600(24)00407-7","article-title":"Vanzacaftor\u2013tezacaftor\u2013deutivacaftor for children aged 6\u201311 years with cystic fibrosis (RIDGELINE trial VX21-121-105): an analysis from a single-arm, phase 3 trial","volume":"13","author":"Hoppe","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.yapd.2025.11.001_bib8","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S2213-2600(24)00411-9","article-title":"Vanzacaftor\u2013tezacaftor\u2013deutivacaftor versus elexacaftor\u2013tezacaftor\u2013ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials","volume":"13","author":"Keating","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.yapd.2025.11.001_bib9","first-page":"43","article-title":"Gastrointestinal manifestations of cystic fibrosis","volume":"12","author":"Sabharwal","year":"2016","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.yapd.2025.11.001_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fgstr.2024.1489876","article-title":"Prevalence and characteristics of gastrointestinal disorders, medication use, and diagnostic interventions in pediatric patients with cystic fibrosis: a nested case\u2013control analysis from the TriNetX EMR-derived global research network real-world dataset","volume":"3","author":"Trocchia","year":"2025","journal-title":"Front Gastroenterol"},{"issue":"41","key":"10.1016\/j.yapd.2025.11.001_bib11","doi-asserted-by":"crossref","first-page":"6322","DOI":"10.3748\/wjg.v26.i41.6322","article-title":"Focus on gastroesophageal reflux disease in patients with cystic fibrosis","volume":"26","author":"Bongiovanni","year":"2020","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10.1016\/j.yapd.2025.11.001_bib12","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.dld.2022.09.005","article-title":"Effects of prolonged proton pump inhibitor treatment on nutritional status and respiratory infection risk in cystic fibrosis: a matched cohort study","volume":"55","author":"Zazzeron","year":"2023","journal-title":"Dig Liver Dis"},{"issue":"3","key":"10.1016\/j.yapd.2025.11.001_bib13","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/ppul.26257","article-title":"Need to study simplification of gastrointestinal medication regimen in cystic fibrosis in the era of highly effective modulators","volume":"58","author":"Sathe","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.yapd.2025.11.001_bib14","doi-asserted-by":"crossref","DOI":"10.1097\/MPA.0000000000002522","article-title":"Gastrointestinal burden in patients with pancreatic insufficient cystic fibrosis before and after Elexacaftor\/Tezacaftor\/Ivacaftor use","author":"Abi-Aad","year":"2025","journal-title":"Pancreas"},{"issue":"5","key":"10.1016\/j.yapd.2025.11.001_bib15","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jcf.2022.06.003","article-title":"Elexacaftor-tezacaftor-ivacaftor improve gastro-oesophageal reflux and sinonasal symptoms in advanced cystic fibrosis","volume":"21","author":"Shakir","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.yapd.2025.11.001_bib16","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/MOP.0000000000000934","article-title":"Pancreatic complications in children with cystic fibrosis","volume":"32","author":"Sellers","year":"2020","journal-title":"Curr Opin Pediatr"},{"issue":"4","key":"10.1016\/j.yapd.2025.11.001_bib17","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jcf.2023.02.013","article-title":"Acute pancreatitis in pancreatic-insufficient cystic fibrosis patients treated with CFTR modulators","volume":"22","author":"Sadras","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.yapd.2025.11.001_bib18","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jcf.2021.09.010","article-title":"CFTR modulators increase risk of acute pancreatitis in pancreatic insufficient patients with cystic fibrosis","volume":"21","author":"Gould","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.yapd.2025.11.001_bib19","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jcf.2022.08.008","article-title":"Cystic fibrosis transmembrane conductance regulator modulators and the exocrine pancreas: a scoping review","volume":"22","author":"Ramsey","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.yapd.2025.11.001_bib20","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1159\/000538606","article-title":"Improved nutritional outcomes and gastrointestinal symptoms in adult cystic fibrosis patients treated with elexacaftor\/tezacaftor\/ivacaftor","volume":"42","author":"Stastna","year":"2024","journal-title":"Dig Dis"},{"issue":"6","key":"10.1016\/j.yapd.2025.11.001_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.71156","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on fecal Elastase-1 in children with cystic fibrosis","volume":"60","author":"Sankararaman","year":"2025","journal-title":"Pediatr Pulmonol"},{"issue":"5","key":"10.1016\/j.yapd.2025.11.001_bib22","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jcf.2021.03.018","article-title":"Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy","volume":"20","author":"Fortner","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.yapd.2025.11.001_bib23","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.jcf.2024.06.003","article-title":"Clinical outcomes of two infants with cystic fibrosis, including presence of the vas deferens, born to a woman with cystic fibrosis taking CFTR modulators during both pregnancies","volume":"23","author":"Kowalik","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.yapd.2025.11.001_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2025.09.004","article-title":"Real-world pancreatic function recovery and fluctuation in young children with cystic fibrosis on elexacaftor\/tezacaftor\/ivacaftor","author":"Schembri","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.yapd.2025.11.001_bib25","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1002\/ppul.26982","article-title":"Predicting weight gain in patients with cystic fibrosis on triple combination modulator","volume":"59","author":"Stewart","year":"2024","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.yapd.2025.11.001_bib26","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.clnu.2025.04.027","article-title":"Dietary intake remains unchanged while nutritional status improves in children and adults with cystic fibrosis on elexacaftor\/tezacaftor\/ivacaftor","volume":"50","author":"Enaud","year":"2025","journal-title":"Clin Nutr"},{"issue":"2","key":"10.1016\/j.yapd.2025.11.001_bib27","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jcf.2022.10.003","article-title":"Elexacaftor\/Tezacaftor\/ivacaftor and gastrointestinal outcomes in cystic fibrosis: report of promise-GI","volume":"22","author":"Schwarzenberg","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.yapd.2025.11.001_bib28","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.jcf.2023.08.002","article-title":"The impact of elexacaftor\/tezacaftor\/ivacaftor on fat-soluble vitamin levels in people with cystic fibrosis","volume":"22","author":"Hergenroeder","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.yapd.2025.11.001_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/children10020252","article-title":"Nutritional status and circulating levels of fat-soluble vitamins in cystic fibrosis patients: a cohort study and evaluation of the effect of CFTR modulators","volume":"10","author":"Francalanci","year":"2023","journal-title":"Children"},{"issue":"Suppl 1","key":"10.1016\/j.yapd.2025.11.001_bib30","first-page":"S70","article-title":"The gastrointestinal microbiome, small bowel bacterial overgrowth, and microbiome modulators in cystic fibrosis","volume":"59","author":"Green","year":"2024","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.yapd.2025.11.001_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.medmic.2022.100057","article-title":"Intestinal dysbiosis and inflammation in cystic fibrosis impacts gut and multi-organ axes","volume":"13","author":"Wrigley-Carr","year":"2022","journal-title":"Med Microecol"},{"issue":"5","key":"10.1016\/j.yapd.2025.11.001_bib32","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jcf.2024.05.002","article-title":"Impact of extended elexacaftor\/tezacaftor\/ivacaftor therapy on the gut microbiome in cystic fibrosis","volume":"23","author":"Marsh","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.yapd.2025.11.001_bib33","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.01935-23","article-title":"Longitudinal profiling of the intestinal microbiome in children with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor","volume":"15","author":"Reasoner","year":"2024","journal-title":"mBio"},{"issue":"4","key":"10.1016\/j.yapd.2025.11.001_bib34","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jcf.2025.05.006","article-title":"Fecal microbiota changes in people with cystic fibrosis after 6 months of elexacaftor\/tezacaftor\/ivacaftor: findings from the promise study","volume":"24","author":"Duong","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.yapd.2025.11.001_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2025.01.010","article-title":"Longer term follow-up of abdominal symptoms (CFAbd-Score) after initiation of elexacaftor\/tezacaftor\/ivacaftor in adults with cystic fibrosis","author":"Caley","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.yapd.2025.11.001_bib36","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jcf.2023.10.001","article-title":"Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and calprotectin over one year of treatment with Elexacaftor-Tezacaftor-Ivacaftor in people with CF aged \u226512 years - the RECOVER study","volume":"23","author":"Mainz","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.yapd.2025.11.001_bib37","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jcf.2023.12.004","article-title":"The gut microbiota in adults with cystic fibrosis compared to colorectal cancer","volume":"23","author":"Caley","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"18","key":"10.1016\/j.yapd.2025.11.001_bib38","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMra2216474","article-title":"Cystic fibrosis","volume":"389","author":"Taichman","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.yapd.2025.11.001_bib39","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.jcf.2024.08.001","article-title":"A longitudinal study assessing the impact of elexacaftor\/tezacaftor\/ivacaftor on gut transit and function in people with cystic fibrosis using magnetic resonance imaging (MRI)","volume":"23","author":"Yule","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.yapd.2025.11.001_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0328015","article-title":"Effect of cystic fibrosis transmembrane conductance regulator modulators and dedicated cystic fibrosis gastrointestinal clinic visits on the incidence of distal intestinal obstructive syndrome in persons with cystic fibrosis","volume":"20","author":"Wongjarupong","year":"2025","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.yapd.2025.11.001_bib41","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1164\/rccm.200505-840OE","article-title":"Cystic fibrosis since 1938","volume":"173","author":"Davis","year":"2006","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Advances in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065310125000295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065310125000295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T19:44:26Z","timestamp":1784922266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065310125000295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0065310125000295"],"URL":"https:\/\/doi.org\/10.1016\/j.yapd.2025.11.001","relation":{},"ISSN":["0065-3101"],"issn-type":[{"value":"0065-3101","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gastrointestinal and Pancreatic Manifestations of Cystic Fibrosis in the Era of Highly Effective Modulators","name":"articletitle","label":"Article Title"},{"value":"Advances in Pediatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yapd.2025.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}